<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01897428</url>
  </required_header>
  <id_info>
    <org_study_id>HL-BPT-101</org_study_id>
    <nct_id>NCT01897428</nct_id>
  </id_info>
  <brief_title>PK Comparisons of Bepotastine Besilate 10 mg and Bepotastine Salicylate 9.64 mg</brief_title>
  <official_title>Clinical Trial to Evaluate Pharmacokinetic Characteristics of Belion in Healthy Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Korea University Anam Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Hanlim Pharm. Co., Ltd.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Korea University Anam Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      To compare the relative bioavailability and pharmacokinetic characteristics of a newly
      developed bepotastine formulation, bepotastine salicylate, with a conventional formulation,
      bepotastine besilate, in healthy subjects with a single dose, randomized, open-label,
      2-sequence -2period crossover study.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>April 2011</start_date>
  <completion_date type="Actual">August 2011</completion_date>
  <primary_completion_date type="Actual">May 2011</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>bepotastine pharmacokinetics: peak plasma concentrations (Cmax)</measure>
    <time_frame>24 hr</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Bepotastine Pharmacokinetics: Area under the time vs. plasma concentration curve from 0 to 24 hr(AUCall)</measure>
    <time_frame>24 hr</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Bepotastine Pharmacokinetics: Area under the time vs. plasma concentration curve from 0 to infinity(AUCinf)</measure>
    <time_frame>24 hr</time_frame>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">26</enrollment>
  <condition>Allergic Rhinitis</condition>
  <condition>Urticaria</condition>
  <condition>Pruritus</condition>
  <arm_group>
    <arm_group_label>Reference arm</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Treated with Reference (bepotastine besilate 10 mg)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Test arm</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Treated with Test (bepotastine salicylate 9.64 mg)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Test-Bepotastine salicylate 9.64 mg</intervention_name>
    <arm_group_label>Test arm</arm_group_label>
    <other_name>Berion</other_name>
    <other_name>Manufactured by Hanlim Pharm. Co., Ltd, Seoul, Korea</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Reference-bepotastine besilate 10 mg</intervention_name>
    <arm_group_label>Reference arm</arm_group_label>
    <other_name>Tarion</other_name>
    <other_name>Manufactured by Dong-A Pharm. Co., Ltd, Seoul, Korea</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  subjects aged between 20 and 45 years

          -  Body weight &gt; 50 kg (in case of female &gt; 45 kg) with BMI between 18 and 29 kg/m2

          -  Signed and dated informed consent form which meets all criteria of current FDA and
             KFDA regulations

        Exclusion Criteria:

          -  subjects with acute conditions.

          -  presence of history affecting ADME

          -  Clinically significant history or current evidence of a hepatic, renal,
             gastrointestinal, or hematologic abnormality

          -  Hepatitis B, hepatitis C, or HIV infection revealed on the laboratory findings

          -  Any other acute or chronic disease

          -  A history of hypersensitivity to bepotastine

          -  A history of alcohol or drug abuse

          -  Participation in another clinical trial within 2 months

          -  smoked &gt;10 cigarettes daily

          -  consumption over 5 glasses daily of beverages containing xanthine derivatives

          -  use of any medication having the potential to affect the study results within 10 days
             before the start of the study.

          -  medication of the inhibitors or inducers of DME including barbiturates within 1 month

          -  one of abnormal lab findings as like

               -  c. AST/ALT &gt; UNL (upper normal limit) x 1.5

               -  Total bilirubin &gt; UNL x 1.5
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Dept. of Clinical Pharmacology &amp; Toxicology, Anam Hospital</name>
      <address>
        <city>Seoul</city>
        <zip>136-705</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>March 2011</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 9, 2013</study_first_submitted>
  <study_first_submitted_qc>July 11, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 12, 2013</study_first_posted>
  <last_update_submitted>July 11, 2013</last_update_submitted>
  <last_update_submitted_qc>July 11, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 12, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Korea University Anam Hospital</investigator_affiliation>
    <investigator_full_name>Ji-Young Park</investigator_full_name>
    <investigator_title>Associate Professor of Clinical Pharmacology</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Rhinitis</mesh_term>
    <mesh_term>Rhinitis, Allergic</mesh_term>
    <mesh_term>Urticaria</mesh_term>
    <mesh_term>Pruritus</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Salicylates</mesh_term>
    <mesh_term>Salicylic Acid</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

